TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2279256

Group type: EXPERIMENTAL
Intervention: Ibopamine 200 mg b.i.d.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Digoxin (open titrated)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 368088

Group type: EXPERIMENTAL
Intervention: Oxprenolol (180 to 480 mg daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propranolol (180 to 480 mg daily)
Number of subjects: 20
Study: 31018690

Group type: EXPERIMENTAL
Intervention: High-fidelity trainer
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Low-fidelity trainer
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Trained cohort (high-fidelity and low-fidelity combined)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no simulator exposure)
Number of subjects: 34
Study: 30036571

Group type: EXPERIMENTAL
Intervention: Filgrastim 5 µg/kg/day i.v. from day 7 post-transplant until neutrophil recovery
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 145
Study: 27486672

Group type: EXPERIMENTAL
Intervention: Active ear acupuncture points identified in infants with NAS
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Psychovegetative rim identified as the most common active somatic area
Number of subjects: 30
Study: 24762094

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dulaglutide 2.0 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sitagliptin (100 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22371876

Group type: EXPERIMENTAL
Intervention: Telephone-based counseling using a motivational interviewing framework (n = 1046)
Number of subjects: 2087

Group type: COMPARATOR
Intervention: Control group receiving mailed educational materials (n = 1041)
Number of subjects: 2087
Study: 19460067

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17568965

Group type: EXPERIMENTAL
Intervention: Exposure to alcohol advertising around schools in sixth grade
Number of subjects: 2586

Group type: EXPERIMENTAL
Intervention: Nonusers of alcohol in sixth grade
Number of subjects: 2586
Study: 15365963

Group type: EXPERIMENTAL
Intervention: Hemofiltration (HF)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Hemodiafiltration (HDF)
Number of subjects: 39
Study: 11880966

Group type: EXPERIMENTAL
Intervention: d4T-NVP-RTV
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: d4T-NVP-NFV
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: d4T-3TC-NFV (3 times daily)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: d4T-3TC-NVP-NFV
Number of subjects: 181
Study: 10452470

Group type: EXPERIMENTAL
Intervention: Amphotericin B lipid emulsion (1.0 mg/kg per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amphotericin B dextrose (0.5 mg/kg per day)
Number of subjects: 0
Study: 7872342

Group type: EXPERIMENTAL
Intervention: ACEI (enalapril or lisinopril)
Number of subjects: 31
Study: 2222130

Group type: EXPERIMENTAL
Intervention: 25% per week taper of short half-life benzodiazepines
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 25% per week taper of long half-life benzodiazepines
Number of subjects: 63
Study: 410133

Group type: EXPERIMENTAL
Intervention: T-suction drainage tubes placed in the vaginal vaults during operation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no T-suction drainage)
Number of subjects: 100
Study: 30611640

Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg/kg
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Haloperidol 5 mg
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo (intravenous distilled water)
Number of subjects: 185
Study: 29289941

Group type: EXPERIMENTAL
Intervention: Azithromycin (5-day course)
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1400
Study: 26130355

Group type: EXPERIMENTAL
Intervention: Bracing
Number of subjects: 68

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 68
Study: 23863909

Group type: EXPERIMENTAL
Intervention: 4 doses of GAD-alum (4D)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: 2 doses of GAD-alum (2D)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 21747340

Group type: EXPERIMENTAL
Intervention: Partogram
Number of subjects: 7827

Group type: EXPERIMENTAL
Intervention: Partogram with defined management protocols
Number of subjects: 7827

Group type: COMPARATOR
Intervention: Partogram versus no partogram
Number of subjects: 7827

Group type: EXPERIMENTAL
Intervention: Partogram with two-hour action line
Number of subjects: 7827

Group type: EXPERIMENTAL
Intervention: Partogram with three-hour action line
Number of subjects: 7827

Group type: EXPERIMENTAL
Intervention: Partogram with alert line
Number of subjects: 7827

Group type: EXPERIMENTAL
Intervention: Earlier intervention
Number of subjects: 7827
Study: 19343928

Group type: EXPERIMENTAL
Intervention: Sealapex (group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: NaOCl/Sealapex (group C)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EDTA/NaOCl/Sealapex (group D)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Etch-and-rinse (Single Bond) and self‐etching (Clearfil SE Bond) adhesives
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EDTA followed by NaOCl treatment
Number of subjects: 40
Study: 17082991

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 19
Study: 15571006

Group type: EXPERIMENTAL
Intervention: Silymarin
Number of subjects: 177

Group type: COMPARATOR
Intervention: Multivitamin supplements
Number of subjects: 177
Study: 15037686

Group type: EXPERIMENTAL
Intervention: Nasal sumatriptan (10 mg for 20-39 kg; 20 mg for >40 kg)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 10460981

Group type: EXPERIMENTAL
Intervention: Foot reflexology at zones corresponding to the right kidney
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo treatment on other foot zones
Number of subjects: 32
Study: 7567488

Group type: EXPERIMENTAL
Intervention: Semiocclusive hydroactive wound dressing
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Occlusive hydrocolloid dressing
Number of subjects: 250

Group type: COMPARATOR
Intervention: Conventional absorbent dressing
Number of subjects: 250
Study: 2329393

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine oral rinse used as a preoperative rinse and immediate postextraction irrigant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.05% cetylpyridium used as a preoperative rinse and postextraction saline irrigation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postextraction irrigation with normal saline
Number of subjects: 0
Study: 7247088

Group type: EXPERIMENTAL
Intervention: Subcutaneous epinephrine combined with aerosol placebo
Number of subjects: 25

Group type: COMPARATOR
Intervention: Aerosol epinephrine with injected placebo
Number of subjects: 25
Study: 31961854

Group type: EXPERIMENTAL
Intervention: OFC (orbitofrontal cortex)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OFC (orbitofrontal cortex) and HPC (hippocampus)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPC-OFC connectivity
Number of subjects: 0
Study: 30396317

Group type: EXPERIMENTAL
Intervention: QIV-GC3110A
Number of subjects: 1299

Group type: COMPARATOR
Intervention: TIV-Yamagata
Number of subjects: 1299

Group type: COMPARATOR
Intervention: TIV-Victoria
Number of subjects: 1299
Study: 26869148

Group type: EXPERIMENTAL
Intervention: l-theanine (200 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: caffeine (160 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: theanine-caffeine combination
Number of subjects: 20

Group type: COMPARATOR
Intervention: black tea (one cup)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo (distilled water)
Number of subjects: 20
Study: 25302852

Group type: EXPERIMENTAL
Intervention: Thalidomide-prednisone
Number of subjects: 332

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 332
Study: 23727083

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 83

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 83

Group type: COMPARATOR
Intervention: Atorvastatin 80 mg vs Atorvastatin 10 mg
Number of subjects: 83
Study: 21856001

Group type: EXPERIMENTAL
Intervention: 0.3 mg intravenous ramosetron (group A)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 0.1 mg oral ramosetron (group B)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Combination of 0.1 mg oral and 0.3 mg intravenous ramosetron (group C)
Number of subjects: 124
Study: 19074686

Group type: EXPERIMENTAL
Intervention: Mirror Therapy (MT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control Therapy (CT)
Number of subjects: 36
Study: 17920916

Group type: EXPERIMENTAL
Intervention: Melphalan and prednisone plus thalidomide (MPT; n=125)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Melphalan and prednisone (MP; n=196)
Number of subjects: 447

Group type: COMPARATOR
Intervention: Reduced-intensity stem cell transplantation using melphalan 100 mg/m2 (MEL100; n=126)
Number of subjects: 447
Study: 15277909

Group type: EXPERIMENTAL
Intervention: Clonidine (0.2 mg orally and as a patch) administered the night before surgery and on the morning of surgery
Number of subjects: 190
Study: 11504278

Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg (Days 1-7) and 400 mg (Days 8-28)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Modafinil 200 mg and 400 mg + Methylphenidate 20 mg (Days 22-28)
Number of subjects: 32
Study: 9692692

Group type: EXPERIMENTAL
Intervention: Budesonide 6 mg daily
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Budesonide 3 mg daily
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 8160597

Group type: EXPERIMENTAL
Intervention: Implantable cardiac defibrillator
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Antiarrhythmic drugs (amiodarone or sotalol)
Number of subjects: 1000
Study: 29784559

Group type: EXPERIMENTAL
Intervention: Anodic stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cathodic stimulation
Number of subjects: 0
Study: 27601500

Group type: EXPERIMENTAL
Intervention: Cycling exercise
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cycling and resistance exercise
Number of subjects: 31

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 31
Study: 23870670

Group type: EXPERIMENTAL
Intervention: Ragweed MATA MPL (short ragweed pollen allergoid adsorbed to L‐Tyrosine + MPL)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study: 22784406

Group type: EXPERIMENTAL
Intervention: Problem-based learning intervention
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Critical reading intervention
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study: 20828584

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing counseling sessions
Number of subjects: 452
Study: 19017582

Group type: EXPERIMENTAL
Intervention: Quit Smoking Network (QSN) intervention condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active Lives control condition
Number of subjects: 0
Study: 16736336

Group type: EXPERIMENTAL
Intervention: Robot-assisted Nissen fundoplication
Number of subjects: 20

Group type: COMPARATOR
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 20
Study: 12763714

Group type: EXPERIMENTAL
Intervention: Mailed stage-targeted print intervention (single mailing of a letter and full-color booklets)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 462
Study: 10793597

Group type: EXPERIMENTAL
Intervention: Fenoterol (10 puffs via metered dose inhaler)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ipratropium (10 puffs via metered dose inhaler)
Number of subjects: 16
Study: 8762211

Group type: EXPERIMENTAL
Intervention: Nifedipine gastrointestinal therapeutic system (30 mg/day)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Nifedipine retard (20 mg twice a day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 1560686

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (FRI, n = 30)
Number of subjects: 84

Group type: COMPARATOR
Intervention: N-hyoscine butylbromide (HBB, n = 25)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Pentazocine (PTZ, n = 29)
Number of subjects: 84
Study: 4008907

Group type: EXPERIMENTAL
Intervention: Dynamic radionuclide imaging (GE scintigraphy) after acid loading and maneuvers (Valsalva, abdominal compression)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Redefined abnormal reflux index greater than 1.7%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 30
Study: 30497799

Group type: EXPERIMENTAL
Intervention: Perceived usefulness of information for mood self-management at T1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Severity of depressive symptoms at T0
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mental health-related quality of life at T0
Number of subjects: 120
Study: 29517671

Group type: EXPERIMENTAL
Intervention: McGrath videolaryngoscope (ML group)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Macintosh laryngoscope (DL group)
Number of subjects: 44
Study: 27084733

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia (IH) combined with body weight‐supported treadmill training (BWSTT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normoxia (Nx) combined with body weight‐supported treadmill training (BWSTT)
Number of subjects: 0
Study: 24432350

Group type: EXPERIMENTAL
Intervention: Presence of an intimate other
Number of subjects: 126

Group type: COMPARATOR
Intervention: Presence of an experimenter
Number of subjects: 126

Group type: COMPARATOR
Intervention: Alone, aware of video recording
Number of subjects: 126
Study: 21822745

Group type: EXPERIMENTAL
Intervention: Carbonated thin liquids (CTL)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Noncarbonated thin liquids (NCTL)
Number of subjects: 17
Study: 21175024

Group type: EXPERIMENTAL
Intervention: Bandtite glass ionomer cement
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Granitec glass ionomer cement
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ariadent glass ionomer cement
Number of subjects: 75
Study: 17085459

Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study: 16135638

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 11907490

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH)
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 9444341

Group type: EXPERIMENTAL
Intervention: 24‐ga IV needle size
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Prolonged tourniquet time
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Underfilling of Vacutainer tubes
Number of subjects: 38
Study: 7617471

Group type: EXPERIMENTAL
Intervention: Nicardipine (NCR) at doses of 1.0 mg, 1/4 mg, 1/16 mg, or 1/64 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control portography without NCR
Number of subjects: 30
Study: 2239717

Group type: EXPERIMENTAL
Intervention: Theophylline (400 mg twice a day)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg twice a day)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combination treatment (theophylline and atenolol)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 684774

Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hormonal therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hormonal therapy combined with external irradiation
Number of subjects: 0
Study: 31074576

Group type: EXPERIMENTAL
Intervention: BOOST‐TLC program (motivational telephone calls for 24 months)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (monthly automated phone message reminders)
Number of subjects: 104
Study: 30392473

Group type: EXPERIMENTAL
Intervention: 10 g refined cold-pressed flaxseed oil providing 4.7 g ALA (n 29)
Number of subjects: 59

Group type: COMPARATOR
Intervention: 10 g high-oleic sunflower oil as control (n 30)
Number of subjects: 59
Study: 28913833

Group type: EXPERIMENTAL
Intervention: Conjoint family‐based treatment (FBT)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Parent‐focused treatment (PFT)
Number of subjects: 107
Study: 26531186

Group type: EXPERIMENTAL
Intervention: Cardiotocography augmented by fetal scalp blood lactate analysis
Number of subjects: 600

Group type: COMPARATOR
Intervention: Cardiotocography alone
Number of subjects: 600
Study: 24018697

Group type: EXPERIMENTAL
Intervention: Grammatically complete prompts
Number of subjects: 5

Group type: COMPARATOR
Intervention: Telegraphic prompts
Number of subjects: 5
Study: 21549069

Group type: EXPERIMENTAL
Intervention: IL‐18 levels in sepsis group
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: IL‐10 levels in sepsis group
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: IL‐18 levels in death group vs survival group
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: IL‐10 levels in death group vs survival group
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: IL‐18/IL‐10 ratio in non-survivors vs survivors
Number of subjects: 38
Study: 19203564

Group type: EXPERIMENTAL
Intervention: 0.03% meloxicam solution (1 drop t.i.d. for 30 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.1% diclofenac solution (1 drop t.i.d. for 30 days)
Number of subjects: 0
Study: 17577461

Group type: EXPERIMENTAL
Intervention: CS-706 10 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CS-706 50 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CS-706 100 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CS-706 200 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Celecoxib 400 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 15204271

Group type: EXPERIMENTAL
Intervention: Effort perception at the shoulder
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Effort perception at the torso
Number of subjects: 31
Study: 12561647

Group type: EXPERIMENTAL
Intervention: Allergenic extract pollen Cynodon dactylon (L) Pers skin prick test
Number of subjects: 200

Group type: COMPARATOR
Intervention: Healthy control group (no intervention)
Number of subjects: 200
Study: 9660536

Group type: EXPERIMENTAL
Intervention: Intermittent schedule (IS), oral administration of UFT (130 mg/m2/b.i.d.) with 2 days rest a week
Number of subjects: 10

Group type: COMPARATOR
Intervention: Continuous schedule (CS), consecutive administration of UFT (130 mg/m2/b.i.d.)
Number of subjects: 10
Study: 8122955

Group type: EXPERIMENTAL
Intervention: Relapse prevention plus desipramine hydrochloride
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Clinical management plus desipramine
Number of subjects: 139

Group type: COMPARATOR
Intervention: Relapse prevention plus placebo
Number of subjects: 139

Group type: COMPARATOR
Intervention: Clinical management plus placebo
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Relapse prevention
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Clinical management
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Depressed subjects
Number of subjects: 139
Study: 2501967

Group type: EXPERIMENTAL
Intervention: Subcutaneous infusion of GHRH (1-29)NH2 at doses of 5 and 10 micrograms/kg/hour
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Oral pyridostigmine 60 mg
Number of subjects: 5
Study: 367457

Group type: EXPERIMENTAL
Intervention: Agar (1 g/kg/day) orally in 4 daily doses from the 1st to the 5th day of life
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study: 29308939

Group type: EXPERIMENTAL
Intervention: Kinesio Taping® (standard treatment plus application of Kinesio Taping® on the respiratory muscles)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (medication and standard physiotherapy treatment)
Number of subjects: 62
Study: 27749236

Group type: EXPERIMENTAL
Intervention: Anti-TNF inhibitors
Number of subjects: 23
Study: 26176044

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 45
Study: 23121563

Group type: EXPERIMENTAL
Intervention: Hb concentration of 7·3 g dL(‐1) (restrictive group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hb concentration of 8·9 g dL(‐1) (liberal group)
Number of subjects: 50
Study: 20354452

Group type: EXPERIMENTAL
Intervention: 6 mg/m MMC on day 1 and 125 mg/m irinotecan on days 2 and 9 (arm A)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 3 mg/m MMC on days 1 and 8 and 125 mg/m irinotecan on days 2 and 9 (arm B)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Both arms (A and B)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Arm A
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Arm B
Number of subjects: 76
Study: 18606949

Group type: EXPERIMENTAL
Intervention: Intensive early-intervention program (OPUS)
Number of subjects: 547

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 547
Study: 16098423

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention for bifurcation lesions
Number of subjects: 11482

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention for nonbifurcation lesions
Number of subjects: 11482
Study: 12546581

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Length of stay (LOS)
Number of subjects: 49
Study: 10885880

Group type: EXPERIMENTAL
Intervention: Light mask illuminated at 1700 lux, with popliteal light pads extinguished
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Popliteal light pads illuminated (13,000 lux) and light mask at < 3 lux
Number of subjects: 3

Group type: COMPARATOR
Intervention: No illumination from light pads applied to the popliteal fossae, with light mask maintained at < 3 lux
Number of subjects: 3